Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication

The rapid spread of the virus, the surge in the number of deaths, and the unavailability of specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID-19 activity. SARS-CoV-2 enters the host cell and assembles a multisubunit RNA-dependent RNA polymerase (RdRp) complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirzada, Rameez Hassan, Haseeb, Muhammad, Batool, Maria, Kim, MoonSuk, Choi, Sangdun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146643/
https://www.ncbi.nlm.nih.gov/pubmed/33946869
http://dx.doi.org/10.3390/cells10051052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146643/
https://www.ncbi.nlm.nih.gov/pubmed/33946869
http://dx.doi.org/10.3390/cells10051052

Ejemplares similares